
ï“

Pharma Germany criticizes EU-US customs agreement and points to supply risks

by | Aug 25, 2025 | Politics

Pharma Deutschland is sticking to its criticism of the new EU-US trade agreement, which provides for an import tariff of 15 percent on medicines from the EU. Despite a certain degree of planning security due to the customs cap, the association sees a structural risk for international healthcare and the European pharmaceutical industry.

Symbolic image. Credits: cottonbrow studio/pexels
Symbolic image. Credits: cottonbrow studio/pexels

The introduction of the tariff ends the previous Zero Customs Pact, which has strengthened the competitiveness and innovation of the industry as well as the European pharmaceutical strategy, especially in times of crisis. Pharma Deutschland is calling for targeted countermeasures, including further negotiations to completely exempt pharmaceuticals from tariffs again, as well as a trade policy that ensures security of supply and competitiveness. According to the association, the ongoing Section 232 investigations in the USA offer an opportunity to emphasize the importance of duty-free treatment for the global supply of medicines.

Pharma Deutschland, the pharmaceutical industry association with the largest number of members in Germany, represents around 400 companies with around 80,000 employees. These provide almost 80 percent of over-the-counter and two-thirds of prescription medicines in German pharmacies.


Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.